


Declaration of Interests Register

TA Committee D Publication Date: 12/08/2020

Topic: Entrectinib for treating NTRK fusion-positive solid tumours [ID1512]

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Dr Peter Hall	TAC D Committee Member	Indirect	Institute had received funding from Roche and Pfizer on unrelated topics.	NA	20/11/2019	NA	It was agreed that this declaration would not prevent Dr Hall from participating in this section of the meeting.
Professor David Meads	TAC D Committee Member	Indirect	Institute had received funding from Janssen on unrelated topics.	NA	24/10/2019	NA	It was agreed that this declaration would not prevent Professor Meads from participating in this section of the meeting.
Amanda Matse- Orere	TAC D Committee Member	Direct - financial	Works for the same group of companies as Roche Products.	NA	04/11/2019	NA	It was agreed that this declaration would prevent Amanda Matse-Orere from participating in this section of the meeting.
Dr Debashis Sarker	Clinical Expert	Indirect	Lead on a Familiarisation Programme for next generation sequencing services provided by Roche (Foundation One in vitro diagnostic assay) with Guy's	NA	08/04/2019	NA	It was agreed that this declaration would not prevent Dr Sarker from participating in this section of the meeting.



			and St Thomas' NHS Foundation Trust.				
Dr Matthew Krebs	Clinical Expert	Direct - financial	Undertaken advisory boards and consultancy with Roche in relation to the drug under review and Foundation Medicine One genomic profiling	NA	15/03/2019	NA	It was agreed that these declarations would not prevent Dr Krebs from participating in this section of the meeting.
		Direct – non- financial	An active investigator in the STARTRK2 study that continues to evaluate the efficacy and safety of entrectinib in TRK fusion positive patients.				
		Indirect	The Christie Hospital NHS Foundation trust receives funding for a number of Roche sponsored clinical trials.				
			The Christie NHS Foundation Trust has a collaboration with Roche to evaluate Foundation Medicine testing				
			Chief investigator on an unrelated investigator-led clinical trial that receives Roche support for Foundation Medicine testing				